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Identification of cell signaling  mechanisms mediating seizure-related 
neuronal death and epileptogenesis is 
important for developing more effective 
therapies for epilepsy. The mammalian 
target of rapamycin (mTOR) pathway 
has recently been implicated in regulat-
ing neuronal death and epileptogenesis 
in rodent models of epilepsy. In par-
ticular, kainate-induced status epilep-
ticus causes abnormal activation of the 
mTOR pathway, and the mTOR inhibi-
tor, rapamycin, can decrease the devel-
opment of neuronal death and chronic 
seizures in the kainate model. Here, we 
discuss the significance of these findings 
and extend them further by identifying 
upstream signaling pathways through 
which kainate status epilepticus activates 
the mTOR pathway and by demonstrat-
ing limited situations where rapamycin 
may paradoxically increase mTOR acti-
vation and worsen neuronal death in the 
kainate model. Thus, the regulation of 
seizure-induced neuronal death and epi-
leptogenesis by mTOR is complex and 
may have dual, opposing effects depend-
ing on the physiological and pathologi-
cal context. Overall, these findings have 
important implications for designing 
potential neuroprotective and antiepi-
leptogenic therapies that modulate the 
mTOR pathway.
Introduction
Epilepsy is one of the most common 
neurological disorders, affecting approxi-
mately 1% of people, and is characterized 
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by significant morbidity and mortality. 
Although there are a variety of underly-
ing causes for epilepsy, seizures themselves 
are often implicated in causing progres-
sive epileptogenesis and neuronal death, 
contributing to medically-intractable epi-
lepsy and co-morbid cognitive deficits. 
Currently available medications simply 
suppress seizure symptomatically, but do 
not appear to prevent seizure-induced 
brain injury or reverse the underlying 
mechanisms of epileptogenesis.1 Thus, it 
is now widely recognized that novel thera-
pies for epilepsy need to be developed that 
have neuroprotective, antiepileptogenic or 
disease-modifying properties.2-4
In order to develop disease-modifying 
therapies for epilepsy, a better under-
standing of the cellular and molecu-
lar mechanisms of epileptogenesis and 
seizure-induced brain injury is required. 
While traditionally seizure medications 
have targeted ion channels and neurotrans-
mitters receptors that directly contribute 
to neuronal excitability, a recent trend 
has been to identify and target primary 
cell signaling pathways that initially trig-
ger downstream mechanisms mediating 
neuronal injury and epileptogenesis. The 
mammalian target of rapamycin (mTOR) 
signaling pathway represents a ratio-
nal candidate, because mTOR regulates 
numerous cellular functions and mecha-
nisms that affect cell survival and death, 
neuronal excitability and epileptogenesis.5 
Furthermore, available drugs exist that 
specifically inhibit mTOR and could be 
readily tested as neuroprotective and anti-
epileptogenic therapies for epilepsy.
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cell growth are primarily accomplished by 
stimulation of protein synthesis. mTOR 
triggers activity of ribosomal S6 kinase-1 
(S6K1), which phosphorylates the ribo-
somal protein S6, promoting ribosomal 
biogenesis and protein translation.14-16 In 
addition, mTOR induces an inhibition 
of the elongation factor 4E binding pro-
tein 1 (4EBP1) and subsequent activation 
(release of inhibition) of the mRNA elon-
gation initiation factor 4E (eIF4E), also 
triggering protein synthesis.15,16 Parallel 
to regulation of the S6K/S6 and 4EBP1/
eIF4E pathways in stimulating protein 
synthesis and cell growth, other signal-
ing elements downstream from mTOR, 
such as p27/cyclin-dependent kinases, 
are responsible for mediating mTOR 
regulation of cell cycle progression and 
proliferation.17-19 Furthermore, mTOR 
may directly modulate separate mecha-
nisms controlling neuronal death, such 
as the pro-apoptotic molecules, BAD and 
Bcl-2.20,21 Overall, the mTOR signaling 
pathway is in a central position to serve as 
a master regulator of multiple, interrelated 
functions and mechanisms relevant to cell 
growth, proliferation and death.
mTOR: A Central Regulator 
of Seizure-Related Neuronal Death 
and Epileptogenesis
The mTOR pathway has emerged as a 
leading candidate for a signaling mecha-
nism that could be involved in seizure-
related neuronal death and epileptogenesis 
in several types of epilepsy.5 In mouse 
models of the genetic epilepsy, Tuberous 
Sclerosis Complex, excessive activity of 
the mTOR pathway due to inactiva-
tion of the upstream regulators, TSC1 or 
TSC2, promotes epileptogenesis, neuro-
nal hypertrophy and glial proliferation, 
and the mTOR inhibitor, rapamycin, 
prevents the development of epilepsy and 
the underlying cellular and histological 
brain abnormalities in these mice.22,23 
Rapamycin also reverses similar histologi-
cal and behavioral abnormalities in related 
genetic models with abnormal mTOR 
signaling due to upstream PTEN gene 
inactivation.24-26 By analogy, given the 
central role of mTOR in multiple cellular 
functions relevant to neuronal survival 
and excitability, the mTOR pathway has 
response to environmental stimuli or intra-
cellular signals, including nutrient and 
energy status, growth factors and stress 
(Fig. 1). Thus, during anabolic states in 
the presence of nutrients, growth factors 
or insulin, specific upstream regulators, 
such as the phosphatidylinositol-3 kinase 
(PI3K)/Akt (protein kinase B) pathway, 
stimulate mTOR, leading to increased pro-
tein synthesis, cellular growth and prolif-
eration.10,11 In catabolic states with energy 
or oxygen deprivation, other upstream 
pathways, such as AMP-kinase (AMPK), 
inhibit mTOR activity, thus limiting pro-
tein translation and cellular growth, pro-
liferation and metabolism.12,13 Activation 
or inhibition of mTOR by upstream path-
ways is generally accomplished through 
opposing effects on the tuberous sclerosis 
gene products, hamartin and tuberin, and 
the small GTPase protein, Rheb.
Downstream from mTOR, there are 
multiple signaling pathways that mediate 
the various functional effects of mTOR 
(Fig. 1). The anabolic actions of mTOR on 
mTOR: A Central Regulator 
of Protein Synthesis, Cell Growth 
and Cell Death
mTOR is a serine-threonine protein kinase 
that is highly conserved among species and 
is implicated in a number of basic cellu-
lar functions, broadly related to growth, 
proliferation, survival, homeostasis and 
death.6-9 Under physiological conditions of 
cellular growth and anabolism, the mTOR 
pathway becomes activated and promotes 
protein synthesis, increased cell size, and 
cellular proliferation, whereas during states 
of metabolic stress or catabolism, mTOR 
activity may be inhibited, thus limiting 
these cellular processes. mTOR has also 
been implicated in regulating neuronal 
death, in particular apoptosis, although 
this relationship is complicated, with 
mTOR having both pro-apoptotic and 
anti-apoptotic actions depending on the 
physiological or pathological conditions.
A number of upstream signaling 
 pathways can modulate mTOR activity in 
Figure 1. regulation and effectors of the mtOr signaling pathway. in response to environmental 
or physiological stimuli, upstream pathways, primarily involving cascades of protein kinases, 
may either activate (Pi3K/akt) or inhibit (aMPK) mtOr via modulation of the tuberin-hamartin 
complex and rheb GtPase (not shown). in turn, mtOr controls multiple downstream pathways/
effectors that individually modulate cell growth and protein synthesis, cell cycle and proliferation, 
and cell death/apoptosis. abbreviations: 4eBP1, elongation factor 4e binding protein 1; aMPK, 
aMP-activated protein kinase; eiF4e, elongation initiation factor 4e; mtOr, mammalian target of 
rapamycin; Pi3K, phosphatidylinositide-3 kinase.
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also been implicated in mediating neuro-
nal death and epileptogenesis in rodent 
models of acquired epilepsy due to brain 
injury. The mTOR pathway is activated in 
animal models of traumatic brain injury 
(TBI) and rapamycin has neuroprotective 
effects against neuronal death and func-
tional deficits following TBI, although 
effects on posttraumatic epilepsy have not 
been described.27,28 mTOR is also trig-
gered in the pilocarpine model of acquired 
epilepsy and mediates axonal sprouting, a 
putative mechanism of epileptogenesis.29 
In a recent study, we have reported that 
the mTOR pathway is involved in neu-
ronal death and epileptogenesis in the 
related kainate model of limbic epilepsy 
in rats.30 In the kainate model, an initial 
episode of prolonged seizures (status epi-
lepticus), induced by administration of 
the glutamate agonist, kainate, triggers 
neuronal death and other cellular and 
molecular changes that promote epilep-
togenesis. After recovery from the status 
epilepticus and following a latent period 
of days to weeks, these changes lead to the 
development of spontaneous seizures. In 
this model, we showed that kainate causes 
activation of the mTOR pathway both 
acutely during status epilepticus and more 
chronically for several weeks coinciding 
with the latent period of epileptogenesis.30 
The mTOR inhibitor rapamycin prevents 
the abnormal kainate-induced mTOR 
activation and, depending on the timing 
of the rapamycin administration, causes 
a variable decrease in putative cellular 
mechanisms of epileptogenesis, includ-
ing hippocampal neuronal death, neuro-
genesis and axonal sprouting. Rapamycin 
also causes a corresponding decrease in the 
development of spontaneous seizures.30 
Thus, these studies suggested that mTOR 
plays a critical role in activating multiple 
downstream mechanisms of neuronal 
injury and epileptogenesis in the kainate 
model and that rapamycin has neuropro-
tective and antiepileptogenic actions in 
this model.
Figure 2. Kainate status epilepticus activates akt, an upstream regulator of the mtOr pathway. 
western blots of hippocampal homogenates were performed at various time points following 
kainate status epilepticus in adult rats. Compared to control rats, the ratio of P-akt to total akt was 
increased acutely with kainate status epilepticus and remained elevated for several weeks.  
*p < 0.05, **p < 0.01 by aNOva, compared to the control group.
Figure 3. rapamycin causes paradoxical exacerbation of kainate-induced mtOr activation when 
administered within one hour of kainate. adult rats were injected with vehicle (Con), kainate 
(15 mg/kg, i.p.), or rapamycin (6 mg/kg) at different intervals before or after kainate. Kainate 
alone (Ka) causes increased mtOr activation, as reflected by the ratio of phospho-S6 to total S6 
expression measured 7 days after kainate injection, compared to vehicle (Con). Pretreatment with 
rapamycin one day prior to kainate inhibits the kainate-induced mtOr activation (Pre-1d). in con-
trast, rapamycin administered within one hour before (Pre-1 h) or after (Post-1 h) kainate causes a 
paradoxical increase in the kainate-induced mtOr activation. *p < 0.05, ***p < 0.001 by aNOva, 
compared to the Ka group.
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Paradoxical Activation of the 
mTOR Pathway and Exacerbation 
of Neuronal Death by Rapamycin 
in the Kainate Model
The number and complexity of upstream 
and downstream signaling pathways and 
mechanisms that may regulate and medi-
ate the effects of mTOR, as well as mul-
tiple positive and negative feedback steps 
that occur among these pathways, suggest 
that the mTOR pathway may have com-
plicated, potentially dual effects on some 
cellular functions. For example, depend-
ing on the physiological or pathological 
conditions, mTOR activation has been 
demonstrated to have both pro-apoptotic 
and anti-apoptic effects.20,21 In pilot stud-
ies to determine effective dosing regimens 
of rapamycin for inhibiting the kainate-
induced mTOR activation,30 we initially 
observed a paradoxical exacerbation of 
the increased mTOR pathway activity, as 
reflected by downstream P-S6 expression, 
when rapamycin and kainate were admin-
istered within a short time period of each 
other. Thus, in our published studies, we 
only injected rapamycin at least twenty-
four hours before (pretreatment) or after 
(posttreatment) kainate in order to obtain 
the expected inhibition of mTOR activ-
ity.30 Further analysis of the initial para-
doxical phenomenon has confirmed that 
rapamycin administered within one hour 
of kainate injection causes a higher level 
of mTOR activation than kainate in the 
absence of rapamycin (Fig. 3). If rapamy-
cin is injected at greater intervals from the 
kainate, the expected inhibition of mTOR 
activation is again observed. The para-
doxical mTOR activation by rapamycin 
is associated with greater neuronal death 
several days after kainate status epilepti-
cus (Fig. 4). Thus, under limited circum-
stances, it appears that rapamycin causes 
a paradoxical activation of the mTOR 
pathway, and depending on the situation, 
rapamycin has the potential to have either 
neuroprotective or exacerbating effects on 
cell death.
The specific molecular mechanisms 
leading to this paradoxical activation of 
the mTOR pathway by rapamycin in the 
kainate model are unknown. A speculative 
explanation is that during periods of espe-
cially high mTOR activity, such as during 
of the mTOR pathway (Fig. 1). Other 
recent studies from our lab support that 
Akt is activated by kainate status epilep-
ticus acutely and more chronically over a 
couple of weeks, correlating with mTOR 
pathway activation that occurs during the 
latent period of epileptogenesis (Fig. 2). 
In contrast, no acute alterations in activa-
tion of the AMPK signaling pathway, also 
upstream from mTOR, were observed 
with kainate (data not shown). In addi-
tion to further defining the cell signal-
ing mechanisms involved, these findings 
provide potential additional strategies 
for preventing seizure-induced neuronal 
death and epileptogenesis, as the Akt/
PI3K could be targeted with specific PI3K 
inhibitors.
Upstream Activation of the mTOR 
Pathway by Kainate-Induced  
Status Epilepticus
The specific mechanisms involved in 
mTOR pathway regulation of seizure-
related neuronal death and epileptogene-
sis deserve further attention. In particular, 
the upstream signaling pathways that 
trigger mTOR activation in the kainate 
model are not known. Given that kain-
ate is a glutamate agonist and that large 
amounts of endogenous glutamate are 
released during status epilepticus, a ratio-
nal hypothesis is that stimulation of the 
Akt/PI3K pathway by glutamate31,32 and 
calcium influx during kainate status epi-
lepticus causes the downstream activation 
Figure 4. rapamycin causes paradoxical exacerbation of kainate-induced cell death when admin-
istered within one hour of kainate. Kainate status epilepticus causes cell death in the Ca1 region 
of hippocampus, as detected by Fluoro-Jade B (FJB) staining 7 days after status epilepticus. Pre-
treatment with rapamycin one day prior to kainate inhibits the kainate-induced neuronal death 
(Pre-1d). in contrast, rapamycin administered within one hour before (Pre-1 h) or after (Post-1 h) 
kainate causes a paradoxical increase in the kainate-induced cell death. *p < 0.05, ***p < 0.001 by 
aNOva, compared to the Ka group.
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the acute phase of kainate-induced seizure 
activity, mTOR inhibition by rapamycin 
may allow alternative feed forward path-
ways for stimulating downstream mTOR 
effectors, such as P-S6, to be activated 
and overcompensate for direct mTOR 
inhibition. Future studies are needed to 
define these mechanisms. Irregardless of 
the specific mechanisms, these findings 
 highlight the complexity of the involve-
ment of the mTOR pathway in responding 
to upstream stimuli and in turn, regulat-
ing downstream effectors. The mTOR 
pathway may have opposing effects on 
mechanisms of neuronal death and epi-
leptogenesis, depending on the situation. 
This has direct clinical implications for 
the use of mTOR inhibitors as potential 
neuroprotective and antiepileptogenic 
agents, as there could be circumstances in 
which such treatment could worsen neuro-
logical status.
Conclusions
mTOR is a central signaling pathway that 
regulates a number of important cellular 
functions and mechanisms involved in sei-
zure-related cell death and epileptogenesis. 
Work in animal models of both genetic and 
acquired epilepsies suggests that modula-
tors of the mTOR pathway may have bene-
ficial neuroprotective and antiepileptogenic 
effects. However, paradoxical effects of 
mTOR inhibition have also been observed 
and suggest that mTOR may serve as a 
master switch that can trigger opposing 
actions on neuronal death and epileptogen-
esis under different conditions. This dual 
role of mTOR needs to be considered in 
designing potential therapies for epilepsy 
that modulate the mTOR pathway.
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